Back to Directory Richard Bertz Email richard.bertz@bms.com Institution Clinical Discovery Title Director-Virology Request an Update Affiliated Studies P1020A: A Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS-232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and Experienced HIV-infected Infants, Children and Adolescents DAIDS Number 10037 Research Area Treatment Study Status Concluded
P1020A: A Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS-232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and Experienced HIV-infected Infants, Children and Adolescents DAIDS Number 10037 Research Area Treatment Study Status Concluded
